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OBJECTIVE: To describe persistence patterns in the use of statin
therapy in a U.S. managed care population. METHODS: Three
years of pharmacy and eligibility claims data from a managed
care health plan with over two million members were utilized.
Patients with at least one paid statin prescription claim in 2002
were identiﬁed. Those with continuous eligibility for six-month
pre- and two-year post-index statin prescription and no statin
claims in a six-month washout period were included. Patients
with statin prescriptions ﬁlled at mail order pharmacies were
excluded. Individuals were followed for 2 years and proportion
of days covered (PDC) was calculated at 6, 12, 18, and 24
months to assess medication persistence. Days supplied for over-
lapping reﬁlls and last censored ﬁll were adjusted to account for
changes in statin therapy, early reﬁll, and days supplied beyond
the study period. RESULTS: A total of 14,047 patients met the
study criteria. Twenty percent were greater than 65 years of age,
56% were male, 20.5% had at least one diabetes-related pre-
scription, 63.5% had atorvastatin as index drug, and median age
was 55. Mean PDC at 6, 12, 18, and 24 months were 0.63, 0.54,
0.49, and 0.47 respectively. At 6 months, only 42.1% of the
study population remained adherent with their statin therapy,
with PDC of at least 80%. By 24-months, only 26% were adher-
ent. Patients taking diabetes related medications had higher
prevalence of adherence than their non-diabetic counterparts
after 6 months and this trend continued for all subsequent time
intervals over two years (p < 0.002). CONCLUSIONS: Adher-
ence rate of statin therapy remains suboptimal in this managed
care population. Programs to maintain patients on statin therapy
are essential to improve health outcomes and reduce drug
wastage costs due to therapy non-compliance.
PCV51
OUTPATIENT DISCONTINUATION AND RESTARTING OF
POST-MYOCARDIAL INFARCTION BETA-BLOCKER THERAPY
Do TP, Gardner JS, Johnson ES, Blough DK, Heckbert SR
University of Washington, Seattle, WA, USA
OBJECTIVE: To estimate the one-year cumulative incidence of
discontinuation of post-MI beta-blocker therapy after hospital
discharge and the one-year cumulative incidence of restarting
therapy following discontinuation. METHODS: We conducted
a retrospective, population-based, inception cohort study among
all enrollees (n = 1334) of Group Health Cooperative (GHC, a
health maintenance organization) aged 30–79 years who sur-
vived a ﬁrst hospitalized MI during 1986–1996 (mean follow up
1.4 years) and were discharged from the hospital on beta-blocker
therapy. Using the GHC computerized pharmacy database, we
calculated the duration of therapy by assuming subjects were on
average 80% compliant with each beta-blocker prescription ﬁll.
We considered subjects to have discontinued therapy on the 60th
consecutive day they were without medication and to have
restarted therapy on the ﬁrst day they obtained a prescription ﬁll
following discontinuation. In sensitivity analyses, we varied
when we considered subjects to have discontinued therapy (i.e.,
on the 30th and the 90th consecutive day without medication).
We estimated the cumulative incidence using failure time analy-
ses. RESULTS: By one year post-discharge, 511 subjects discon-
tinued therapy; the cumulative incidence of discontinuation was
39.0% (95% CI: 36.3, 41.6). The cumulative incidence increased
to 50.7% (95% CI: 47.9, 53.3) and decreased to 33.4% (95%
CI: 30.9, 36.0) when our discontinuation deﬁnition required 30
and 90 days without medication, respectively. By one year post-
discontinuation, the cumulative incidence of restarting was
42.7% (95% CI: 39.1, 46.2). The cumulative incidence of
restarting increased to 52.9% (95% CI: 49.6, 56.1) and
decreased to 32.0% (95% CI: 28.4, 35.6) when our discontinu-
ation deﬁnition required 30 and 90 days without medication,
respectively. CONCLUSIONS: Our results indicate that patients
are likely to restart post-MI beta-blocker therapy after having
discontinued it. Studies considering only time to ﬁrst discontin-
uation may be oversimplifying the long-term utilization patterns
of therapy by misclassifying patients who subsequently restart.
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OBJECTIVES: The objectives of this study were to investigate
factors associated with adherence to medications for diabetes
and hyperlipidemia, and to assess the impact of adherence on
hospitalization risk. METHODS: Administrative claims and
cash prescriptions data from Wolters Kluwer Health’s IHR data-
base were utilized. This extensive database provides longitudinal
prescription history on about 157 million patients, prescription
and physician services’ history on about 35 million, and pre-
scription, physician services’ and hospitalization history on
about 6 million patients. Adult patients initiating therapy for
either condition between July 2003 and June 2004 and having
claims activity in the 12 months period prior to and following
the index prescription were identiﬁed. A Medication Possession
Ratio °Y´ 80% was considered to be indicative of adherence.
Hospitalization risk was deﬁned as the probability of being
admitted to a hospital in post-index period. Logistic regression
was employed to identify predictors of adherence including: age,
gender, payer type, charlson index, chronic disease score, pres-
ence of disease conditions and pill burden. Relationship between
hospitalization risk and adherence was also modeled using logis-
tic regression after adjusting for the same covariates described
previously. RESULTS: About 48.4% of the 116,607 diabetes
patients and 38.5% of the 285,853 hyperlipidemia patients were
adherent. Predictors of improved adherence in both disease
groups were male gender, being a Medicaid beneﬁciary, a higher
chronic disease score and lower pill burden. Comorbid diseases
including AMI, CAD, CHF, stroke and hyperlipidemia were
associated with higher adherence in the diabetes group. For both
disease conditions, hospitalization risk was signiﬁcantly higher
in non-adherent patients [Diabetes OR: 1.47 (p < 0.0001),
Hyperlipidemia OR: 1.24 (p < 0.0001)]. CONCLUSIONS:
Adherence to therapy is suboptimal for diabetes and hyperlipi-
demia, two chronic diseases that are major drivers of health care
spending. Furthermore, non-adherent patients faced a signiﬁ-
cantly higher risk of hospitalization compared to adherent
patients.
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OBJECTIVES: Examine the relationship of statin noncompli-
ance to subsequent hospitalization among new statin users after
coronary heart disease (CHD) hospitalization. METHODS:
Medstat Marketscan 1999–2002 databases including inpatient,
outpatient and pharmacy claims were utilized for this study. The
ﬁrst statin prescription ﬁll date within six months of CHD hos-
pitalization was identiﬁed as the index date. The sample con-
sisted of adults who had no statin use during the year prior to
the CHD hospitalization and had at least 2-years continuous
